Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
Proceeds to fund global Phase 3 registration program for the company’s lead product candidate, Obexelimab, and suppo…
Continue ReadingProceeds to fund global Phase 3 registration program for the company’s lead product candidate, Obexelimab, and suppo…
Continue Readingโดยทางบริษัทได้ดำเนินการให้ทุ
NE…
Continue Reading
Many people evacuated from vulnerable locations in the northwestern Bahamas as Tropical Storm Nicole approac…
Continue ReadingThe U.S. Supreme Court appeared likely Wednesday to leave in place most of a federal law that gives preference to Native …
Continue Reading– BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling